Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Gastroenterol
Main Authors: Nadinskaia, Maria, Maevskaya, Marina, Ivashkin, Vladimir, Kodzoeva, Khava, Pirogova, Irina, Chesnokov, Evgeny, Nersesov, Alexander, Kaibullayeva, Jamilya, Konysbekova, Akzhan, Raissova, Aigul, Khamrabaeva, Feruza, Zueva, Elena
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2021
Teme:
Clinical Trials Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7968130/
https://ncbi.nlm.nih.gov/pubmed/33776366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v27.i10.959
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki